Figure S3

A: 

SIRPα/α - ADCC

SW48 (wt) - panitumumab/cetuximab

Killing (%)

Concentration (µg/mL)

---

B: 

% killing all donors – ADCC

SW48 (wt) - panitumumab/cetuximab

---

C: 

Pmab and Cmab fold enhancement

all donors – ADCC

SW48 (wt) - panitumumab/cetuximab

---

D: 

EC50 all donors - ADCC

SW48 (wt) - panitumumab/cetuximab

---

E: 

BYON4228 and isotype fold enhancement

all donors – ADCC

SW48 (wt) - panitumumab/cetuximab

---

F: 

% killing all donors – ADCC

SW48 (wt or mutant) - panitumumab

---

G: 

EC50 all donors - ADCC

SW48 (wt or mutant) - panitumumab

---

H: 

BYON4228 and isotype fold enhancement

all donors – ADCC

SW48 (wt or mutant) - panitumumab

---